Mutations within the EGFR signaling pathway: Influence on efficacy in FIRE-3—A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients.
Sebastian Stintzing(Humboldt-Universität zu Berlin), Volker Heinemann(LMU Klinikum), Thomas Decker, Markus Moehler(Johannes Gutenberg University Mainz), Ursula Vehling‐Kaiser(University of Applied Sciences Landshut), Dominik Paul Modest(Berliner Hochschule für Technik), Andreas Jung(Ludwig-Maximilians-Universität München), Salah‐Eddin Al‐Batran(Goethe University Frankfurt), Tobias Heintges(Lukaskrankenhaus), Lisa Rossius(München Klinik), Ludwig Fischer von Weikersthal(Praxis für Hämatologie und Onkologie), Thomas Kirchner(Friedrich-Alexander-Universität Erlangen-Nürnberg), Werner Scheithauer(Comprehensive Cancer Center Vienna), Alexander Kiani(Bayreuth Medical Center)
Cited by 97
Related Papers
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial
|The Lancet|2008|1.9k
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2014|1.7k
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
|New England Journal of Medicine|2021|1.7k